GENMAB A/S |
Market Closed -
Other stock markets
|
After market 21:00:01 | |||
| 25.8 EUR | -0.77% |
|
25.7 | -0.39% |
| 06-04 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
| 06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 19.8B 2.87B 2.65B 226B | Sales 2025 * | 23.62B 3.42B 3.16B 269B | Capitalization | 124B 17.96B 16.6B 1,413B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 678M 627M 53.32B | Net income 2025 * | 6.61B 958M 885M 75.32B | EV / Sales 2024 * | 4.95 x |
| Net cash position 2024 * | 25.92B 3.75B 3.47B 295B | Net cash position 2025 * | 32.36B 4.69B 4.33B 369B | EV / Sales 2025 * | 3.88 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
20.4
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -1.15% | ||
| 1 month | -3.01% | ||
| 3 months | -3.73% | ||
| 6 months | -12.84% | ||
| Current year | -10.42% |
1 week
25.60
26.40
1 month
25.4027.80
Current year
24.4029.80
1 year
24.4038.20
3 years
24.4044.40
5 years
14.5244.40
10 years
14.5244.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 25.8 | -0.77% |
| 06/06/24 | 26 | -0.76% |
| 05/06/24 | 26.2 | +0.77% |
| 04/06/24 | 26 | +0.78% |
| 03/06/24 | 25.8 | 0.00% |
Delayed Quote Börse Stuttgart, June 07, 2024 at 09:31 am
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
10/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,930
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.57B | |
| +3.23% | 22.82B | |
| -41.74% | 16.54B | |
| -13.31% | 16.5B | |
| +2.44% | 13.39B | |
| +27.89% | 11.1B | |
| +83.45% | 9.22B |
- Stock Market
- Equities
- GMAB Stock
- GE91 Stock